Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

Indibviduate1 Jul. 28 at 4:23 AM

$GALT

0 · Reply

SamGantVHee Jul. 28 at 2:45 AM

$GALT breaking out of upper vwap channel last week! Want to see consolidation this week 2.70s to 3.10s before we gap up. Ideally if it can hold 2.88 and consolidate above that range entirely above the upper vwap channel would show major strength

1 · Reply

TheBigMaccccc Jul. 28 at 1:56 AM

$GALT

1 · Reply

Stock_Catcher Jul. 27 at 11:49 PM

Money Monday Watchlist Pt.13 $SOAR $SBFM $GALT $TOVX $RMTI Let's Have A Good Time Tomorrow 📈

0 · Reply

ThomasLD Jul. 27 at 9:51 PM

$GALT You said “… when it comes to analyzing data on biotechs he (Martin S) seems to know what he’s talking about…” really? @Jimmity I had a Master Degree in Electrical Engineering for more than 3 decades and I know how to read. I read and understood your question “why does J*rk off Martin S seem to cast doubt on GALT from a YouTube I just watched”? I didn’t want to give you a straight answer because you said that you just watched that YouTube and if you are smart, then you should be able to figure out that he did not know how to analyze GALT’s phase 2b/3 data. He was a liar. That is a horrible YouTube, worst than 5th grade level and because of him, his short gang had been trapped for shorting GALT stock below $1.3 lol! SHORT SQUEEZE is coming 💰💰💰💰💰💰Thank you Martin S.

1 · Reply

ThomasLD Jul. 27 at 3:18 PM

$GALT The more I read this the more I think that the company has been setting up for BO by the end of the year even though they just say partnership. Have a good day! https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/ef20051584_8k.htm#:~:text=On%20July%208%2C%202025%2C%20at,prior%20to%20December%2031%2C%202025

3 · Reply

BullsOnParade79 Jul. 27 at 1:40 PM

$GALT lots of people complaining about the short squeeze taking a while to materialize here. It might be a blessing in disguise… Many of you new folks or tired longs would sell this gem if it popped up to $11 and then started to get choppy there. Leaving a lot of potential upside on the table. Maybe the best thing for everyone is a big violent shot upwards on BO news, just saying.

6 · Reply

ThomasLD Jul. 27 at 12:52 PM

$GALT Hi everyone! Do not spend your time and your energy to worry about SHORTS to cover or not to cover. Let them play longer with their own game for a best short squeeze in the US history. When BO hits, it will wipe them out completely similar to Galveston Hurricane of 1900 in the US! Later!

1 · Reply

ThomasLD Jul. 27 at 12:41 PM

Stop worrying about shorts to cover or not cover Dan $GALT @individual1 . Let them play with their game.

1 · Reply

Indibviduate1 Jul. 27 at 11:38 AM

$GALT If the buyout price was just 10 billion shorts would need to raise $96.80 x 7.5 million which is $726,000,000 to cover if they could cover at that averaged buyout price. 726 million. That would be a crippling loss. Seems odd they’re not rushing to cover.

0 · Reply

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 7 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 7 months ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 7 months ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 8 months ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 9 months ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 10 months ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 11 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 1 year ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 1 year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 2 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

May 16, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

Jan 6, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Indibviduate1 Jul. 28 at 4:23 AM

$GALT

0 · Reply

SamGantVHee Jul. 28 at 2:45 AM

1 · Reply

TheBigMaccccc Jul. 28 at 1:56 AM

$GALT

1 · Reply

Stock_Catcher Jul. 27 at 11:49 PM

Money Monday Watchlist Pt.13 $SOAR $SBFM $GALT $TOVX $RMTI Let's Have A Good Time Tomorrow 📈

0 · Reply

ThomasLD Jul. 27 at 9:51 PM

1 · Reply

ThomasLD Jul. 27 at 3:18 PM

3 · Reply

BullsOnParade79 Jul. 27 at 1:40 PM

6 · Reply

ThomasLD Jul. 27 at 12:52 PM

1 · Reply

ThomasLD Jul. 27 at 12:41 PM

Stop worrying about shorts to cover or not cover Dan $GALT @individual1 . Let them play with their game.

1 · Reply

Indibviduate1 Jul. 27 at 11:38 AM

0 · Reply

hardslog Jul. 27 at 10:14 AM

$GALT is Belapectin made in the USA? Could be a strong determining factor when applying for the FDA's new CNPV pilot program.

1 · Reply

Indibviduate1 Jul. 27 at 2:35 AM

$GALT if interest on borrowed shares is declining does that mean there are less shorts interested in borrowing shares?

1 · Reply

ThomasLD Jul. 26 at 11:11 PM

$GALT Let me take the average of ChatGPT’s and LifeSci’s estimation (top $3.7b BO + top $18B peak sales) / 2 = $10.85b BO / 0.112 ~ $96.87 or x2 BO ~ $193+. I still think BO will be in triple digits.

3 · Reply

D_Coral Jul. 26 at 8:16 PM

$GALT $XBI It’s anyone’s guess where a partnership/buyout deal will end up, but I know 100% for sure this stock is worth many multiples above the current price. AI analysis:

4 · Reply

Nunyabid Jul. 26 at 8:01 PM

$GALT

1 · Reply

MaryJaneSmokesalot Jul. 26 at 6:14 PM

$GALT when the billionaire chairman keeps quietly putting millions of his own money into the company, protects shareholders from dilution, and refuses to sell… That’s not a long-shot gambler. That’s a man who knows something.

2 · Reply

ThomasLD Jul. 26 at 5:47 PM

$GALT It should not be complex. BP company will pay for what it is worth for. Example, I won’t buy a car 🚗 for $50K if it is only worth for $10K. On the other hand, the 2025 Rolls-Royce Phantom is a pinnacle of luxury and craftsmanship, featuring a starting price of $517,750 and extending to $597,750 depending on the trim and options. So, I will pay for the 2025 Rolls-Royce Phantom ~ $517,750 minimum and will be happy with it. Same thing with valuable drugs such as Belapectin!

1 · Reply

ThomasLD Jul. 26 at 2:36 PM

$GALT Triple Digits BO!!!!!!! I am not kidding. This is a hidden 💎 gem. Once it is approved, it is too late to get cheap shares. Life sciences estimated $18 peak Belapectin sales in the US! BO is typically x2 x3 or x4 of the peak sales. 112 m OS after dilution. $18/ 0.112 ~ $160! BO ($160 x2 x3 or x4). In addition, Belapectin has other indications such as (Belapectin + Keytruda) that we didn’t talk about. Ignore the internal sales of Belapectin. Concentrate on the US PATENTS ONLY.

1 · Reply

ThomasLD Jul. 26 at 2:11 PM

$GALT We will get more than $160. BO ~ 2 or 3x of the peak sales $18B ($160).

0 · Reply

Indibviduate1 Jul. 26 at 11:03 AM

$GALT In the first half of 2025, Roche experienced strong growth, with a 7% increase in sales (at constant exchange rates). The Pharmaceuticals Division saw a 11% growth in the same period.

0 · Reply

Leerial Jul. 26 at 8:48 AM

$GALT any buyout news? 🚀 The after hours is at $3.14 now 👍

2 · Reply

Indibviduate1 Jul. 26 at 5:41 AM

$GALT Just wish they could make this drug available to the millions of liver disease patients who need it now. Save some lives and give millions of others hope. So frustrating that the shorts are playing such tragic games when the drug is so needed by patients who have nothing else in this unmet need.

0 · Reply

Market Cap	184.18M
Revenue (ttm)	0.00
Net Income (ttm)	-47.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.68

Volume	162,400
Avg Vol	720,414
Day's Range	N/A - N/A
Shares Out	63.29M
Stochastic %K	58%
Beta	0.70
Analysts	Strong Sell
Price Target	$6.00